Opportunity Information: Apply for CDC RFA PS20 2001
The Tuberculosis Elimination and Laboratory Cooperative Agreement (Funding Opportunity Number CDC RFA PS20-2001) is a CDC discretionary cooperative agreement meant to strengthen and modernize the public health response to tuberculosis (TB) in the United States. It builds on decades of CDC support for state and local TB programs and recognizes that, even though U.S. TB case counts have reached historic lows, the country is not on pace to eliminate TB with current approaches alone. The central message of the opportunity is that TB elimination will require not only finding and curing active TB disease, but also expanding efforts to identify and treat latent TB infection (LTBI) among people at highest risk, so infection does not later progress to contagious disease.
The opportunity is grounded in the continued public health importance of TB. TB spreads through the air and remains one of the leading infectious killers worldwide. The notice cites global 2017 estimates of 10.0 million people becoming sick with TB disease and 1.3 million TB-related deaths, with TB described as the leading killer of people living with HIV. In the United States, 9,105 TB cases were reported in 2017 (2.8 per 100,000), representing a small decline from 2016 and the lowest number ever recorded nationally. Despite this progress, CDC emphasizes that elimination will not happen this century without shifting more attention to preventing future cases through LTBI testing and treatment. CDC estimates up to 13.0 million people in the U.S. have LTBI, and the notice highlights that more than 80 percent of U.S. TB cases stem from longstanding, untreated LTBI rather than recent transmission, meaning prevention-focused strategies are essential.
A major theme of the grant is targeting resources where risk is highest and where TB burden is concentrated. The notice describes how TB disproportionately affects specific populations, including people who are non-U.S.-born; people living with HIV infection or diabetes; people experiencing homelessness; people who are incarcerated; and people who use illicit substances. It points out that, in 2017, the TB incidence rate among non-U.S.-born persons was about 15 times higher than among U.S.-born persons, and that the share of U.S. cases occurring in non-U.S.-born persons has continued to rise, reaching 70.1 percent in 2017. The cooperative agreement reinforces an approach centered on high-risk groups, combining the traditional responsibilities of TB prevention and control with a more deliberate, targeted strategy to find and treat LTBI in populations most likely to progress to disease.
Programmatically, the cooperative agreement supports two tightly linked areas of work: TB prevention and control activities and TB laboratory activities. While the notice does not list every required activity in the excerpt provided, its purpose is clear: recipients are expected to sustain and improve the systems that identify people with active TB disease, ensure they are treated successfully, and interrupt transmission, while also implementing targeted testing and treatment for LTBI to prevent future cases. The laboratory component is included because rapid, accurate TB testing underpins diagnosis, drug-resistance detection, and public health decision-making, and strong coordination between program and laboratory functions is necessary for effective TB control and elimination.
The funding is structured as a cooperative agreement, which generally means CDC will have substantial involvement beyond simply issuing funds, such as providing technical assistance, guidance, and collaboration on implementation. The primary responsibility for developing and carrying out TB program and laboratory work remains with state and local health departments, and the funding is explicitly described as complementary to their work. A key condition is that these federal funds are not meant to replace or reduce state and local investments in TB control responsibilities. The notice explicitly mentions examples of costs and responsibilities that should remain supported locally, such as providing medications, inpatient care, and maintaining health department facilities.
Eligibility is geared toward public health agencies and jurisdictions that are positioned to run TB programs at scale. Eligible applicants include state governments, county governments, and city or township governments, with additional eligible entities possible as described in the full announcement. The administering agency is the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), specifically within NCHHSTP. The CFDA number listed is 93.116. The opportunity anticipated 61 awards. The posted award ceiling is listed as 0, which typically signals that the ceiling was not specified in the summary field and applicants would need to consult the full notice for funding ranges, formulas, or jurisdiction-based allocations.
Key dates in the notice indicate it was created on July 5, 2019, with an original closing date of September 5, 2019, and electronic applications due by 11:59 p.m. Eastern Time on the deadline date. Overall, the cooperative agreement is designed to push the U.S. TB response beyond incremental declines in case counts by pairing strong treatment and case management for active TB with a more aggressive, data-driven approach to finding and treating latent infection in high-risk populations, supported by capable public health laboratories and coordinated state and local infrastructure.Apply for CDC RFA PS20 2001
- The Department of Health and Human Services, Centers for Disease Control - NCHHSTP in the health sector is offering a public funding opportunity titled "Tuberculosis Elimination and Laboratory Cooperative Agreement" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.116.
- This funding opportunity was created on Jul 05, 2019.
- Applicants must submit their applications by Sep 05, 2019 Electronically submitted applications must be submitted no later than 1159 p.m., ET, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 61 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the Tuberculosis Elimination and Laboratory Cooperative Agreement?
The Tuberculosis Elimination and Laboratory Cooperative Agreement (Funding Opportunity Number CDC RFA PS20-2001) is a CDC discretionary cooperative agreement intended to strengthen and modernize the public health response to tuberculosis (TB) in the United States. It builds on long-standing CDC support for state and local TB programs and emphasizes that current approaches alone are not sufficient to eliminate TB.
Who is the administering agency for this opportunity?
The administering agency is the U.S. Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), within NCHHSTP.
What is the CFDA number associated with this funding?
The CFDA number listed for this opportunity is 93.116.
What is the central goal of this cooperative agreement?
The central goal is to move the United States closer to TB elimination by supporting both (1) strong identification and treatment of active TB disease and (2) expanded, targeted efforts to identify and treat latent TB infection (LTBI) among people at highest risk, so infection does not later progress to contagious TB disease.
Why does the CDC emphasize latent TB infection (LTBI) in this funding opportunity?
The notice emphasizes that TB elimination will not occur this century without shifting more attention to prevention, including LTBI testing and treatment. CDC estimates up to 13.0 million people in the U.S. have LTBI, and the notice highlights that more than 80% of U.S. TB cases stem from longstanding, untreated LTBI rather than recent transmission.
How is TB described in terms of public health importance in this notice?
The opportunity is grounded in TB's continued public health importance. TB spreads through the air and remains one of the leading infectious killers worldwide. The notice cites global 2017 estimates of 10.0 million people becoming sick with TB disease and 1.3 million TB-related deaths, and it describes TB as the leading killer of people living with HIV.
What does the notice say about TB trends in the United States?
The notice reports that 9,105 TB cases were reported in the U.S. in 2017 (2.8 per 100,000), a small decline from 2016 and the lowest number ever recorded nationally. Despite historically low case counts, CDC states the country is not on pace to eliminate TB with current approaches alone.
Which populations are highlighted as being disproportionately affected by TB?
The notice indicates TB disproportionately affects specific populations, including people who are non-U.S.-born; people living with HIV infection or diabetes; people experiencing homelessness; people who are incarcerated; and people who use illicit substances.
What does the notice say about TB among non-U.S.-born persons?
The notice states that, in 2017, the TB incidence rate among non-U.S.-born persons was about 15 times higher than among U.S.-born persons. It also notes that the proportion of U.S. TB cases occurring in non-U.S.-born persons has continued to rise, reaching 70.1% in 2017.
What kinds of work does the cooperative agreement support?
The cooperative agreement supports two closely linked areas of work: (1) TB prevention and control activities and (2) TB laboratory activities. The notice emphasizes sustaining and improving systems to identify active TB disease, ensure successful treatment, and interrupt transmission, while also implementing targeted testing and treatment for LTBI to prevent future cases.
Why is there a laboratory component in this cooperative agreement?
The laboratory component is included because rapid, accurate TB testing underpins diagnosis, drug-resistance detection, and public health decision-making. The notice also stresses that strong coordination between program and laboratory functions is necessary for effective TB control and elimination.
What does it mean that this funding is a cooperative agreement?
A cooperative agreement generally means CDC will have substantial involvement beyond simply issuing funds, such as providing technical assistance, guidance, and collaboration on implementation. The primary responsibility for developing and carrying out TB program and laboratory work remains with state and local health departments.
Is this funding intended to replace state or local TB control funding?
No. The notice explicitly states that these federal funds are complementary to state and local work and are not meant to replace or reduce state and local investments in TB control responsibilities.
What are examples of costs and responsibilities that should remain supported by state and local resources?
The notice provides examples of costs and responsibilities that should remain supported locally, including providing medications, inpatient care, and maintaining health department facilities.
Who is eligible to apply for this opportunity?
Eligibility is geared toward public health agencies and jurisdictions positioned to run TB programs at scale. Eligible applicants include state governments, county governments, and city or township governments, with additional eligible entities possible as described in the full announcement.
How many awards were anticipated?
The opportunity anticipated 61 awards.
What is the award ceiling for this funding opportunity?
The posted award ceiling is listed as 0 in the summary information. This typically indicates that a ceiling was not specified in the summary field and that applicants would need to consult the full notice for funding ranges, formulas, or jurisdiction-based allocations.
What are the key dates listed in the notice?
The notice indicates it was created on July 5, 2019, with an original closing date of September 5, 2019. Electronic applications were due by 11:59 p.m. Eastern Time on the deadline date.
What is the main strategy the CDC is promoting through this cooperative agreement?
The main strategy is to pair strong treatment and case management for active TB with a more aggressive, data-driven approach to finding and treating latent infection in high-risk populations, supported by capable public health laboratories and coordinated state and local infrastructure.
How does the notice describe the relationship between active TB control and LTBI work?
The notice frames TB elimination as requiring both: continuing to find and cure active TB disease to stop transmission now, and expanding LTBI identification and treatment among people at highest risk to prevent future cases from developing.
Does the excerpt list every required activity for recipients?
No. The excerpt notes that it does not list every required activity, but it clearly describes the purpose and the two main work areas (TB prevention/control and TB laboratory activities), as well as the emphasis on targeted LTBI testing and treatment alongside active TB case finding and treatment.
What is the funding opportunity number (FON) for this announcement?
The funding opportunity number is CDC RFA PS20-2001.
Browse more opportunities from the same category: Health
Next opportunity: Building Regional Resilience in the Western Balkans
Previous opportunity: Office of Special Education and Rehabilitative Services (OSERS): Rehabilitation Services Administration (RSA): Rehabilitation Training: Innovative Rehabilitative Training Program CFDA Number 84.263C
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA PS20 2001
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA PS20 2001) also looked into and applied for these:
| Funding Opportunity |
|---|
| USAID/Uganda Maternal Child Health and Nutrition (MCHN) Activity Apply for 72061719RFA00001 Funding Number: 72061719RFA00001 Agency: Agency for International Development, Uganda USAID-Kampala Category: Health Funding Amount: $17,500,000 |
| Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed) Apply for RFA OD 19 022 Funding Number: RFA OD 19 022 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $200,000 |
| Maximizing the Scientific Value of Existing Biospecimen Collections: Scientific Opportunities for Exploratory Research (R21 Clinical Trial Not Allowed) Apply for RFA OD 19 021 Funding Number: RFA OD 19 021 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $200,000 |
| Integrated Child Health and Social Services Award (ICHSSA) Apply for 72062019RFA00007 Funding Number: 72062019RFA00007 Agency: Agency for International Development, Nigeria USAID-Abuja Category: Health Funding Amount: $19,500,000 |
| Early Hearing Detection and Intervention Program Apply for HRSA 20 047 Funding Number: HRSA 20 047 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $235,000 |
| PEFO Fence Support Project FY19 Apply for P19AS00394 Funding Number: P19AS00394 Agency: Department of the Interior, National Park Service Category: Health Funding Amount: $65,450 |
| Strengthening Public Health Laboratories Internationally Apply for CDC RFA GH16 17200101SUPP19 Funding Number: CDC RFA GH16 17200101SUPP19 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $10,000,000 |
| USAID Uganda Health Care Waste Management Activity Apply for 72061719RFA00002 Funding Number: 72061719RFA00002 Agency: Agency for International Development, Uganda USAID-Kampala Category: Health Funding Amount: $4,500,000 |
| Request for Information - USAID/Tanzania Community Social Welfare System Strengthening Program (CHSSP) Apply for RFI 621 19 CHSSP Funding Number: RFI 621 19 CHSSP Agency: Agency for International Development, Tanzania USAID-Dar es Salaam Category: Health Funding Amount: $35,000,000 |
| Radiation Exposure Screening and Education Program Apply for HRSA 20 029 Funding Number: HRSA 20 029 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Center of Excellence for Natural Product Drug interaction Research (U54, Clinical Trial Required) Apply for RFA AT 20 002 Funding Number: RFA AT 20 002 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Rural Health Network Development Planning Program Apply for HRSA 20 026 Funding Number: HRSA 20 026 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Early Hearing Detection and Intervention National Technical Resource Center Apply for HRSA 20 048 Funding Number: HRSA 20 048 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: $850,000 |
| WIYIZIRE (Come here, we will support you) Health Activity Apply for RFA 72069519RFA00002 Funding Number: RFA 72069519RFA00002 Agency: Agency for International Development, Burundi USAID-Bujumbura Category: Health Funding Amount: $3,000,000 |
| Household and Community Health and Health Systems Strengthening, Governance and Financing Activities Apply for 72068819RFA00004 Funding Number: 72068819RFA00004 Agency: Agency for International Development Category: Health Funding Amount: $54,000,000 |
| Local Partner Service Delivery Activity (LPSDA) - HIV Clinical, OVC, Family Planning, Reproductive Maternal Neonatal Child Adolescent Health (FP/RMNCAH) Activities Apply for 72061519RFI000003 Funding Number: 72061519RFI000003 Agency: Agency for International Development, East Africa USAID-Kenya Category: Health Funding Amount: $109,200,000 |
| RFI-Local Partner Service Delivery Activity (LPSDA) - OVC Activities Apply for 72061519RFI00001 Funding Number: 72061519RFI00001 Agency: Agency for International Development, East Africa USAID-Kenya Category: Health Funding Amount: $178,100,000 |
| RFI -Local Partner Service Delivery Activity (LPSDA) - Integrated HIV Clinical and Orphaned and Vulnerable Children (OVC) Activities Apply for 72061519RFI00002 Funding Number: 72061519RFI00002 Agency: Agency for International Development, East Africa USAID-Kenya Category: Health Funding Amount: $136,000,000 |
| Building Resources for the Basic Biology of Aging in Health Disparities Research (R24 Clinical Trial Not Allowed) Apply for RFA AG 20 035 Funding Number: RFA AG 20 035 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $300,000 |
| Liberia Community Health Activity Apply for RFI CH LIBERIA Funding Number: RFI CH LIBERIA Agency: Agency for International Development, Liberia USAID-Monrovia Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA PS20 2001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.